Design and study setting
This study was a prospective randomized clinical trial. The cases were recruited at the 1st Affiliated Hospital of Wenzhou Medical University from 15th Sept 2020 to 28th Feb 2022. The Ethics Committee of the First Affiliated Hospital, Wenzhou Medical University granted ethical approval (No.2020–178) and the trial was prospectively registered in the Chinese Clinical Trial Registry on 8th Sept, 2020 (ChiCTR2000037974). This study was conducted in adherence to the principles of the Helsinki Declaration and complied with CONSORT standards. Informed consent in this study was acquired from patients before participation.